Reference health
Blockage of interleukin-1β with canakinumab in patients with Covid-19
35/35 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
4 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 35 checked references that resolve
resolves10.1016/j.jcv.2020.104364
Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China
resolves10.1007/s00134-020-05991-x
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
resolves10.1016/j.jinf.2020.03.005
Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients
resolves10.1016/S0140-6736(20)30628-0
COVID-19: consider cytokine storm syndromes and immunosuppression
resolves10.1016/j.jinf.2020.03.037
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
resolves10.1016/S0140-6736(20)30183-5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
resolves10.23812/CONTI-E
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.
resolves10.1016/j.ijantimicag.2020.105982
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
resolves10.1016/j.medmal.2020.05.001
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
resolves10.1016/S2665-9913(20)30127-2
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
resolves10.1016/j.coph.2004.03.010
Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation
resolves10.1161/CIRCRESAHA.120.315937
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
resolves10.4155/fmc-2019-0301
A Perspective on Targeting Inflammation and Cytokine Actions in Atherosclerosis
resolves10.1016/j.jacc.2018.03.490
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
resolves10.1056/NEJMoa2019014
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
resolves10.3389/fimmu.2020.01942
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome
resolves10.7861/clinmed.2019-coron
What we know so far: COVID-19 current clinical knowledge and research
resolves10.1056/NEJMoa2001282
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
resolves10.1016/S0140-6736(20)30566-3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
resolves10.1136/fmch-2020-000406
Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis
resolves10.1016/j.autrev.2020.102568
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
resolves10.3390/microorganisms8050695
Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
resolves10.1097/CCM.0000000000004363
Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)
resolves10.1002/clc.23451
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)
The 4 references without a DOI — listed, not checked
no DOI — not checked1World Health Organization. Available at: https://covid19.who.int.
no DOI — not checked20SIMIT. Available at: http://www.simit.org/medias/1569-covid19-vademecum-13-03-202.pdf. Accessed 2 May, 2020.
no DOI — not checkedZangrillo, A. et al. Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit. Care Resusc. 22, 200 (2020).
no DOI — not checkedLibby, P., Glynn, R. J., Thuren, T., Hilkert, R. & Ridker, P. M. Understanding and mitigating the risk of infection with canakinumab. Eur. Heart J. 39, 5ehy64 (2018).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1038/s41598-020-78492-y"><img src="https://citestamp.com/citestamped/10.1038/s41598-020-78492-y/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1038/s41598-020-78492-y)